(Q40581672)

21 September 2017

1 reference

title

Pharmacodynamic profile of prostacyclin (English)

1 reference

21 September 2017

1 reference

1

J R Vane

1 reference

21 September 2017

R M Botting

2

1 reference

PubMed ID

7840052

21 September 2017

language of work or name

English

0 references

publication date

1 January 1995

1 reference

American Journal of Cardiology

21 September 2017

1 reference

21 September 2017

75

1 reference

21 September 2017

3

1 reference

21 September 2017

3A-10A

1 reference

The enzymatic formation of prostaglandin E2 from arachidonic acid prostaglandins and related factors 32

21 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

THE BIOSYNTHESIS OF PROSTAGLANDINS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Localisation and stimulation of prostacyclin production in vascular cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Prostacyclin production by isolated adipocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Circulatory and anti-platelet effects of intravenous prostacyclin in healthy men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Prevention of blockage of partially obstructed coronary arteries with prostacyclin correlates with inhibition of platelet aggregation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Anti-aggregatory effect of prostacyclin (PGI2) in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Topical prostacyclin (PGI2) inhibits platelet aggregation in pial venules of the mouse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Modulation of human platelet adenylate cyclase by prostacyclin (PGX)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Stimulation of calcium uptake in platelet membrane vesicles by adenosine 3′,5′-cyclic monophosphate and protein kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Cyclic adenosine 3′,5′-monophosphate and prostacyclin inhibit membrane phospholipase activity in platelets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Cyclic adenosine 3',5'-monophosphate inhibits the availability of arachidonate to prostaglandin synthetase in human platelet suspensions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Cyclic AMP inhibits synthesis of prostaglandin endoperoxide (PGG2) in human platelets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Effect of prostacyclin (PGI2) on platelet adhesion to rabbit arterial subendothelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Role of prostaglandins in the defense of the gastric mucosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Studies on the protective effect of prostacyclin in acute myocardial ischemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Prostacyclin in experimental myocardial ischemia: effects on hemodynamics, regional myocardial blood flow, infarct size and mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Administration of prostacyclin prevents ventricular fibrillation following coronary occlusion in conscious dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Prevention of infarction-induced decrease in circulating platelet count by prostacyclin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Salutary effects of prostacyclin in endotoxic shock

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Twenty-four- and 48-hour canine liver preservation by simple hypothermia with prostacyclin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Prostacyclin prolongs viability of washed human platelets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Profile of circulating vasoactive substances in hemorrhagic shock and their pharmacologic manipulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Effect of hemorrhagic shock on renal release of prostaglandin E

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

The effect of indomethacin on the cardiovascular and metabolic responses to E. coli endotoxin in the cat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Sequential release of tumour necrosis factor, platelet activating factor and eicosanoids during endotoxin shock in anaesthetized pigs; protective effects of indomethacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

The effect of inhibitors of the L-arginine/nitric oxide pathway on endotoxin-induced loss of vascular responsiveness in anaesthetized rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

The release and fate of vaso-active hormones in the circulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Indomethacin and aspirin abolish prostaglandin release from the spleen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

The release of prostaglandins from lung and other tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Some effects of inhibiting endogenous prostaglandin formation on the responses of the cat spleen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Prostaglandin feedback mechanism limits vasoconstrictor action of norepinephrine in perfused rabbit ear

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Generation of prostaglandin E-like material by the guinea-pig trachea contracted by histamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Effect of glucocorticoid on prostaglandin production during simulated shock conditions in the perfused cat liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

The influence of hydrocortisone and indomethacin on the release of prostaglandin-like substances during circulatory shock in cats, which was induced by an intravenous administration of rabbit blood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Endotoxin alters arachidonate metabolism in pulmonary endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Prostacyclin synthesis induced in vascular cells by interleukin-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Interleukin-1 stimulates prostacyclin production by cultured human endothelial cells by increasing arachidonic acid mobilization and conversion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Cachectin/TNF as well as interleukin-1 induces prostacyclin synthesis in cultured vascular endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Nitric oxide-mediated hyporeactivity to noradrenaline precedes the induction of nitric oxide synthase in endotoxin shock

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

The pathogenesis of atherosclerosis--an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Smooth muscle cells and the pathogenesis of the lesions of atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Further studies on the enzymatic conversion of prostaglandin endoperoxide into prostacyclin by porcine aorta microsomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Studies on the role of lipoperoxides in human pathology. II. The presence of peroxidized lipids in the atherosclerotic aorta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

The effect of peroxidized arachidonic acid upon human platelet aggregation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

The generation of prostacyclin by arteries and by the coronary vascular bed is reduced in experimental atherosclerosis in rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Biphasic response of intimal prostacyclin production during the development of experimental atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Increased platelet aggregability is associated with increased protacyclin production by vessel walls in hypercholesterolemic rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Increased Prostacyclin Biosynthesis in Patients with Severe Atherosclerosis and Platelet Activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Prostacyclin generation in atherosclerotic arteries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Treatment of intermittent claudication. A reappraisal of the value of alpha-tocopherol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Prostaglandins and cyclic nucleotides. Modulators of arterial cholesterol metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

The effect of infused prostacyclin in migraine and cluster headache

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Effects of prostacyclin during cardiopulmonary bypass in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Prostacyclin administration during cardiopulmonary bypass in man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

The place of prostacyclin in the clinical management of primary pulmonary hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Prostacyclin and PGE1 treatment of pulmonary hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Aerosolised prostacyclin in adult respiratory distress syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Successful therapy of advanced arteriosclerosis obliterans with prostacyclin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

A double blind placebo controlled trial of intravenous prostacyclin (PGI2) in 108 patients with ischaemic peripheral vascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Intravenous prostacyclin (PGI2) infusion to 108 patients with ischaemic peripheral vascular disease: Phase II-open study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Treatment of Raynaud's phenomenon by intravenous infusion of prostacyclin (PGI2)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

INTERMITTENT EPOPROSTENOL (PROSTACYCLIN) INFUSION IN PATIENTS WITH RAYNAUD'S SYNDROME

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Prostacyclin therapy in patients with congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Retrospective comparison of iloprost with other treatments for secondary Raynaud's phenomenon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

Effect of indomethacin on the blood pressure and plasma catecholamine responses to acute endotoxaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

inferred from DOI database lookup

7 January 2021

based on heuristic

The Role of the l-arginine: Nitric Oxide Pathway in Circulatory Shock

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980377-4

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9149(99)80377-4

1 reference

21 September 2017

1 reference

PubMed ID

7840052